MitoQ attenuates brain damage by polarizing microglia towards the M2 phenotype through inhibition of the NLRP3 inflammasome after ICH

Weixiang Chen,Chao Guo,Suna Huang,Zhengcai Jia,Jie Wang,Jun Zhong,Hongfei Ge,Jichao Yuan,Tunan Chen,Xin Liu,Rong Hu,Yi Yin,Hua Feng
DOI: https://doi.org/10.1016/j.phrs.2020.105122
IF: 10.334
2020-11-01
Pharmacological Research
Abstract:<p>Microglial phenotype plays an important role in secondary injury after intracerebral haemorrhage (ICH), with M1 microglia promoting inflammatory injury and M2 microglia inhibiting neuroinflammation and promoting haematoma absorption. However, there is no effective intervention for regulating the phenotypic transformation of microglia after ICH. This study aimed to elucidate the protective effect of MitoQ, a selective mitochondrial ROS antioxidant, against microglial M1 state polarization and secondary brain injury. The in vivo data showed that MitoQ attenuated neurological deficits and decreased inflammation, oedema and haematoma volume after ICH. In addition, MitoQ decreased the expression of M1 markers and increased the expression of M2 markers both in vivo and in vitro after ICH. Mechanistically, MitoQ blocked overproduction of mitochondrial ROS and activation of the NLRP3 inflammasome in FeCl<sub>2</sub>-treated microglia. Moreover, NLRP3 siRNA shifted FeCl<sub>2</sub>-treated microglia from the M1 to the M2 cells, revealing that MitoQ-induce polarization states may be mediated by the mitochondrial ROS/NLRP-3 pathway. In summary, MitoQ alleviates secondary brain injury and accelerates haematoma resolution by shifting microglia towards the M2 phenotype after ICH.</p>
pharmacology & pharmacy
What problem does this paper attempt to address?
The paper attempts to address the issue of how to mitigate secondary brain injury following Intracerebral Hemorrhage (ICH). Specifically, the authors explore whether MitoQ (a selective mitochondrial ROS antioxidant) can reduce brain edema, promote hematoma absorption, and improve neurological deficits by inhibiting the activation of the NLRP3 inflammasome and promoting the polarization of microglia to the M2 phenotype. This study aims to provide new intervention strategies for post-ICH treatment, particularly focusing on the regulation of microglial polarization to reduce inflammatory responses and brain injury, thereby improving patient outcomes.